TEST PREVIEW

  1. Which of the following statements is TRUE?
  1. Clinical research has consistently demonstrated that plaque mass reduction results in a one-to-one proportionate decrease in gingivitis.
  1. Clinical research on the gingival health and plaque reduction benefits of a stabilized stannous fluoride dentifrice has shown _______________.
  1. Irritants (e.g., bacteria) and injuries trigger inflammation, a biological defense mechanism. Inflammatory mediators are then sent out which cause characteristic signs of acute inflammation. Cytokine production brings about vascular and cellular permeability effects.
  1. Acute inflammation can have a positive effect to heal and restore health, while chronic inflammation has been implicated in several systemic conditions.
  1. Subgingival plaque _______________.
  1. If the gingival ‘early lesion’ is not restored to homeostasis through removal or modulation of the plaque bacteria, which of the following is likely to occur?
  1. Lipopolysaccharide (LPS) and lipoteichoic acid (LTA) are examples of endotoxins released by _______________.
  1. Host toll-like receptors (TLRs) in the gingival sulcus identify bacterial endotoxins as harmful, and then _______________.
  1. All of the following statements about the gingival inflammatory defense mechanism are true, EXCEPT:
  1. The most common characteristic clinical signs of inflammation in the gingival tissues include erythema, edema, and altered contours of the gingival margin.
  1. The efficacy of adjunctive chemotherapeutic oral products like stabilized stannous fluoride is contingent upon plaque quantity being concurrently reduced through mechanical means.
  1. With respect to stannous fluoride, which of the following statement(s) is/are correct?
  1. Bactericidal actions, ______________________, and recently discovered plaque toxicity reduction are all means by which stannous fluoride both prevents and reduces gingivitis.
  1. Stannous fluoride acts to prevent inflammation by binding plaque bacteria endotoxins to block the host inflammatory response.
  1. All of the following statements about the way stannous fluoride (SnF2) disrupts the gingival inflammation process by reducing plaque toxicity are true, EXCEPT:
  1. If stannous fluoride’s insertion in the inflammatory cascade process leading to gingivitis is compared to an alarm clock set to go off, the alarm clock cord is analogous to _______________, and a safety protective cover blocking the outlets is analogous to _______________.
  1. Klukowska et al reported that in a 4-week clinical trial of stannous fluoride with ‘high’ and ‘low’ bleeding site cohorts _______________.
  1. Stannous fluoride’s (SnF2) modulation of the virulence/pathogenicity of gingival sulcus plaque has been shown in new research to likely be tied to these key factors _______________.
  1. Formulation expertise is critical for a stabilized stannous fluoride dentifrice because _______________.
  1. Which of the following statements is TRUE?
  1. Oral chemotherapeutics in common use today include which of the following?
  1. Chlorhexidine works primarily via bactericidal actions. It is considered a gold standard for treating gingivitis. Staining and adverse taste can hinder patient compliance.
  1. Triclosan dentifrices are formulated with a copolymer to maximize oral retention.
  1. A consideration in recommending a cetylpyridinium chloride (CPC) antimicrobial is that it _______________.
  1. Oral chemotherapeutic antimicrobial dentifrices can be an intelligent strategy for improving gingival health because they _______________.
  1. Stannous fluoride is unique among oral antimicrobials in that it _______________.
  1. A challenge with early stannous fluoride dentifrices which has been overcome with today’s advanced stabilized stannous fluoride formulations was _______________.
  1. In subjects with plaque but apparently healthy gingival tissues, susceptibility to later disease is unknown.  In-office testing can be done to ascertain individual genetic factors and predict future risk.
  1. Which of the following patient group(s) could benefit from stabilized antimicrobial stannous fluoride dentifrice use?